

ERRATUM Open Access

## Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Michael Ezrokhi, Shuqin Luo, Yelena Trubitsyna and Anthony H. Cincotta\*

## **Erratum**

After publication of this manuscript [1], we noted errors to the labels of Fig. 7. The Y-axis of panel C was incorrectly labelled as "Plasma Adiponectin, ng/ml" instead of "PEPCK, % of Vehicle". (Please see a corrected version of Fig. 7 below).

Received: 24 February 2015 Accepted: 18 June 2015 Published online: 04 July 2015

## Reference

 Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.

## Submit your next manuscript to BioMed Central and take full advantage of:


- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



<sup>\*</sup> Correspondence: Anthony\_Cincotta@veroscience.com VeroScience LLC, Tiverton, RI 02878, USA





**Fig. 7** Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256 (Panel **a**), glucose-6-phosphatase (Panel **b**), and PEPCK (Panel **c**). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. \*Difference is statistically significant; P values are noted under each panel